PapersFlow Research Brief
Pharmacogenetics and Drug Metabolism
Research Guide
What is Pharmacogenetics and Drug Metabolism?
Pharmacogenetics and Drug Metabolism is the study of genetic variations that influence drug metabolism, particularly through Cytochrome P450 enzymes, affecting pharmacokinetics, drug response, and personalized medicine applications such as warfarin dose estimation.
This field encompasses 83,510 works examining Cytochrome P450 enzymes, genetic polymorphisms, and their roles in xenobiotic metabolism and enzyme activities. Research highlights how genetic variations impact drug pharmacokinetics and personalized dosing strategies. Key focuses include polymorphisms' effects on drug response and estimation of warfarin doses.
Topic Hierarchy
Research Sub-Topics
Cytochrome P450 Polymorphisms and Drug Metabolism
This sub-topic investigates genetic variants in CYP2D6, CYP2C19, CYP3A4/5, and other P450 enzymes affecting metabolic phenotypes from poor to ultra-rapid metabolizers. Researchers correlate star alleles with drug clearance, adverse reactions, and dosing guidelines.
CYP2C9 Variants and Warfarin Dosing
This sub-topic focuses on CYP2C9*2/*3 alleles and VKORC1 polymorphisms predicting warfarin dose requirements and bleeding risk. Researchers develop pharmacogenetic algorithms integrating genotype, age, and comorbidities for personalized anticoagulation.
Drug-Drug Interactions via Cytochrome Induction Inhibition
This sub-topic examines clinically significant P450-mediated interactions where inhibitors like ketoconazole or inducers like rifampin alter victim drug exposure. Researchers quantify DDI magnitude using inhibition constants, induction ratios, and PBPK modeling.
Pharmacogenomics of CYP2D6 Poor Metabolizers
This sub-topic studies CYP2D6 gene duplications, deletions, and inactivating mutations causing poor metabolism of 25% of prescribed drugs including antidepressants and beta-blockers. Researchers implement prospective genotyping to guide alternative therapy selection.
UDP-Glucuronosyltransferase Pharmacogenetics
This sub-topic covers UGT1A1*28 variants causing Gilbert's syndrome and irinotecan toxicity, plus UGT2B7 polymorphisms affecting opioid glucuronidation. Researchers correlate UGT haplotypes with glucuronide formation rates and personalized analgesics.
Why It Matters
Pharmacogenetics and drug metabolism enable personalized medicine by accounting for genetic variations in enzyme activities, improving drug efficacy and reducing adverse reactions. For instance, Daina et al. (2017) in "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules" provide a tool that assesses absorption, distribution, metabolism, and excretion properties, aiding over 15,559 cited studies in drug development. Wishart et al. (2017) in "DrugBank 5.0: a major update to the DrugBank database for 2018" (8,453 citations) supply comprehensive data on drug mechanisms, targets, and interactions, supporting pharmacokinetic modeling influenced by genetic factors. These resources underpin warfarin dose adjustments based on Cytochrome P450 polymorphisms, minimizing bleeding risks in clinical settings.
Reading Guide
Where to Start
"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules" by Daina et al. (2017), as it offers an accessible entry to pharmacokinetics assessment central to understanding genetic influences on drug metabolism.
Key Papers Explained
Daina et al. (2017) in "SwissADME" establishes tools for pharmacokinetics evaluation, which Wishart et al. (2017) in "DrugBank 5.0" extends with drug-target data for pharmacogenetic modeling. Omura and Sato (1964) in "The Carbon Monoxide-binding Pigment of Liver Microsomes" foundationalizes Cytochrome P450 discovery, underpinning genetic variation studies. Chou and Talalay (1984) in "Quantitative analysis of dose-effect relationships" quantifies multi-drug effects modulated by polymorphisms, while Gibaldi and Perrier (1982) in "Pharmacokinetics" provides core principles linking genetics to metabolism.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current work builds on Cytochrome P450 polymorphisms for warfarin dosing and xenobiotic metabolism, with no recent preprints or news indicating ongoing refinements in personalized pharmacokinetic predictions.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | SwissADME: a free web tool to evaluate pharmacokinetics, drug-... | 2017 | Scientific Reports | 15.6K | ✓ |
| 2 | The Carbon Monoxide-binding Pigment of Liver Microsomes | 1964 | Journal of Biological ... | 11.8K | ✓ |
| 3 | Arzneimittelforschung | 2005 | Bundesgesundheitsblatt... | 9.4K | ✕ |
| 4 | Inhibition of Prostaglandin Synthesis as a Mechanism of Action... | 1971 | Nature New Biology | 8.6K | ✕ |
| 5 | DrugBank 5.0: a major update to the DrugBank database for 2018 | 2017 | Nucleic Acids Research | 8.5K | ✓ |
| 6 | Quantitative analysis of dose-effect relationships: the combin... | 1984 | Advances in Enzyme Reg... | 7.1K | ✕ |
| 7 | Drug repurposing: progress, challenges and recommendations | 2018 | Nature Reviews Drug Di... | 4.3K | ✕ |
| 8 | Network pharmacology: the next paradigm in drug discovery | 2008 | Nature Chemical Biology | 4.1K | ✕ |
| 9 | Tissue fractionation studies. 6. Intracellular distribution pa... | 1955 | Biochemical Journal | 4.1K | ✓ |
| 10 | Pharmacokinetics | 1982 | — | 4.1K | ✕ |
Frequently Asked Questions
What role do Cytochrome P450 enzymes play in drug metabolism?
Cytochrome P450 enzymes metabolize drugs and xenobiotics in the liver, with genetic variations altering their activities and impacting pharmacokinetics. Omura and Sato (1964) identified the carbon monoxide-binding pigment in liver microsomes as a key component of these enzymes. Polymorphisms in these enzymes influence drug response and personalized dosing.
How does pharmacogenetics affect warfarin dosing?
Pharmacogenetics examines genetic polymorphisms in Cytochrome P450 enzymes that determine warfarin metabolism and required doses. Variations lead to differences in pharmacokinetics, necessitating personalized dose estimation. This approach reduces risks of over- or under-dosing in patients.
What tools evaluate drug pharmacokinetics?
SwissADME is a free web tool that predicts absorption, distribution, metabolism, and excretion for small molecules. Daina et al. (2017) developed it to assess drug-likeness and medicinal chemistry properties. It supports pharmacogenetic studies by modeling genetic influences on metabolism.
What databases support pharmacogenetic research?
DrugBank 5.0 provides molecular data on drugs, mechanisms, interactions, and targets relevant to metabolism. Wishart et al. (2017) updated it with comprehensive pharmacokinetics information. It aids analysis of genetic variations' effects on drug responses.
How do genetic polymorphisms influence enzyme activities?
Polymorphisms in genes encoding Cytochrome P450 enzymes modify activity levels, altering drug metabolism rates. This affects pharmacokinetics and therapeutic outcomes. Studies link these variations to personalized medicine strategies.
Open Research Questions
- ? How can Cytochrome P450 polymorphisms be integrated into routine clinical pharmacokinetic models for multiple drugs?
- ? What undiscovered genetic variations beyond known polymorphisms most strongly predict warfarin dose requirements?
- ? In what ways do tissue-specific enzyme distributions, as in De Duve et al. (1955), alter predictions of drug metabolism?
- ? How do combined genetic and environmental factors quantitatively affect dose-effect relationships in multi-drug therapies?
- ? Which novel Cytochrome P450 enzyme isoforms emerge under chronic xenobiotic exposure?
Recent Trends
The field maintains 83,510 works with no specified 5-year growth rate, reflecting sustained focus on Cytochrome P450 genetic variations and pharmacokinetics.
High citations persist for foundational papers like Daina et al. at 15,559 and Omura and Sato (1964) at 11,824, with no recent preprints or news signaling shifts.
2017Research Pharmacogenetics and Drug Metabolism with AI
PapersFlow provides specialized AI tools for Pharmacology, Toxicology and Pharmaceutics researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pharmacogenetics and Drug Metabolism with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Pharmacology, Toxicology and Pharmaceutics researchers